PAVmed Financials
PAVM Stock | USD 1.00 0.01 0.99% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 0.43 | 0.4522 |
|
|
The essential information of the day-to-day investment outlook for PAVmed includes many different criteria found on its balance sheet. An individual investor should monitor PAVmed's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in PAVmed.
Net Income |
|
PAVmed | Select Account or Indicator |
Understanding current and past PAVmed Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of PAVmed's financial statements are interrelated, with each one affecting the others. For example, an increase in PAVmed's assets may result in an increase in income on the income statement.
PAVmed Stock Summary
PAVmed competes with Neuropace, Hyperfine, Orthopediatrics Corp, Inari Medical, and Tela Bio. PAVmed Inc. operates as a medical device company in the United States. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York. Pavmed operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US70387R1068 |
CUSIP | 70387R106 70387R403 70387R205 |
Location | New York; U.S.A |
Business Address | 360 Madison Avenue, |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.pavmed.com |
Phone | 917 813 1828 |
Currency | USD - US Dollar |
PAVmed Key Financial Ratios
Return On Equity | -13.58 | ||||
Operating Margin | (13.98) % | ||||
Price To Sales | 2.81 X | ||||
Revenue | 2.45 M | ||||
Gross Profit | (3.24 M) |
PAVmed Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 7.2M | 19.8M | 87.0M | 54.0M | 33.1M | 23.6M | |
Other Current Liab | 1.4M | (15.0M) | 4.3M | 3.7M | 6.6M | 7.0M | |
Net Tangible Assets | (6.1M) | (641K) | 57.2M | (15.8M) | (18.2M) | (17.3M) | |
Net Debt | 1.9M | (2.3M) | (77.3M) | (3.1M) | 29.1M | 30.5M | |
Retained Earnings | (53.7M) | (88.3M) | (138.9M) | (228.2M) | (294.4M) | (279.7M) | |
Accounts Payable | 2.4M | 3.0M | 3.3M | 2.7M | 1.8M | 1.9M | |
Cash | 6.2M | 17.3M | 77.3M | 39.7M | 19.6M | 18.9M | |
Capital Surpluse | 32.6M | 47.6M | 87.6M | 198.1M | 227.8M | 239.2M | |
Other Current Assets | 328.3B | 1.7M | 5.2M | 3.9M | 4.3M | 4.0M | |
Total Liab | 11.9M | 20.3M | 7.6M | 43.0M | 57.1M | 60.0M | |
Total Current Assets | 6.5M | 18.9M | 82.6M | 43.9M | 24.5M | 20.8M | |
Common Stock | 40.5K | 64K | 86K | 95K | 9K | 8.6K | |
Other Assets | 693K | 837K | 725K | 1.1M | 1.0 | 0.95 | |
Net Invested Capital | 2.0M | 14.3M | 59.2M | 21.3M | (12.6M) | (12.0M) | |
Short Long Term Debt | 7.9M | 8.1M | 14.7M | 33.7M | 44.2M | 46.4M | |
Net Working Capital | (5.3M) | (1.0M) | 75.1M | 2.7M | (29.7M) | (28.2M) | |
Short Term Debt | 7.9M | 8.1M | 15.0M | 34.8M | 45.8M | 48.1M | |
Capital Stock | 2.3M | 2.6M | 2.5M | 2.8M | 3.0M | 2.8M |
PAVmed Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 32.7K | 53K | 5.8M | 1.3M | 589K | 559.6K | |
Gross Profit | (14.2K) | (23K) | (85K) | (3.2M) | (4.0M) | (3.8M) | |
Operating Income | (14.3M) | (23.4M) | (54.4M) | (90.9M) | (68.8M) | (65.4M) | |
Ebit | (15.4M) | (35.8M) | (56.1M) | (102.0M) | (78.7M) | (74.7M) | |
Research Development | 6.6M | 11.0M | 19.8M | 25.5M | 14.3M | 9.5M | |
Ebitda | (15.4M) | (35.8M) | (55.9M) | (99.4M) | (75.7M) | (72.0M) | |
Cost Of Revenue | 14.2K | 23K | 585K | 3.6M | 6.4M | 6.7M | |
Income Before Tax | (17.3M) | (35.9M) | (56.1M) | (103.2M) | (79.3M) | (75.3M) | |
Net Income | (15.9M) | (34.3M) | (50.3M) | (101.3M) | (64.2M) | (61.0M) | |
Income Tax Expense | (1.3M) | (1.6M) | (5.8M) | (1.9M) | (13.0B) | (12.3B) | |
Minority Interest | (814K) | (2.4M) | 5.8M | 14.3M | 15.8M | 16.6M | |
Net Interest Income | (582.9K) | (713K) | (523K) | (1.3M) | (448K) | (470.4K) |
PAVmed Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (2.0M) | 11.0M | 60.0M | (37.5M) | (20.1M) | (19.1M) | |
Net Borrowings | 6.2M | 16.7M | (14.8M) | 35.2M | 40.5M | 42.5M | |
Free Cash Flow | (13.4M) | (22.0M) | (42.1M) | (72.5M) | (52.3M) | (49.7M) | |
Depreciation | 14.2K | 23K | 226K | 2.5M | 2.9M | 3.1M | |
Other Non Cash Items | 558.6K | 5.3M | (1.5M) | 11.0M | (3.5M) | (3.3M) | |
Capital Expenditures | 27.2K | 55K | 1.5M | 1.5M | 242K | 377.4K | |
Net Income | (17.3M) | (35.9M) | (56.1M) | (103.2M) | (64.2M) | (61.0M) | |
End Period Cash Flow | 6.2M | 17.3M | 77.3M | 39.7M | 19.6M | 19.0M | |
Change To Netincome | 1.6M | 12.3M | 15.1M | 16.3M | 18.7M | 19.6M | |
Dividends Paid | 67.4B | 357K | 436M | 35.2M | 12.5B | 9.8B | |
Investments | (27.2K) | (55K) | (3.7M) | (4.7M) | 643K | 675.2K |
PAVmed Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining PAVmed's current stock value. Our valuation model uses many indicators to compare PAVmed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PAVmed competition to find correlations between indicators driving PAVmed's intrinsic value. More Info.PAVmed Inc is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, PAVmed's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value PAVmed by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.PAVmed Inc Systematic Risk
PAVmed's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. PAVmed volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on PAVmed Inc correlated with the market. If Beta is less than 0 PAVmed generally moves in the opposite direction as compared to the market. If PAVmed Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one PAVmed Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of PAVmed is generally in the same direction as the market. If Beta > 1 PAVmed moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in PAVmed Stock are looking for potential investment opportunities by analyzing not only static indicators but also various PAVmed's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of PAVmed growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
PAVmed November 24, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of PAVmed help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of PAVmed Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of PAVmed Inc based on widely used predictive technical indicators. In general, we focus on analyzing PAVmed Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build PAVmed's daily price indicators and compare them against related drivers.
Downside Deviation | 6.4 | |||
Information Ratio | 0.0909 | |||
Maximum Drawdown | 63.57 | |||
Value At Risk | (8.93) | |||
Potential Upside | 9.46 |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PAVmed. If investors know PAVmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PAVmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.14) | Revenue Per Share 0.459 | Quarterly Revenue Growth 4.898 | Return On Assets (0.80) | Return On Equity (13.58) |
The market value of PAVmed Inc is measured differently than its book value, which is the value of PAVmed that is recorded on the company's balance sheet. Investors also form their own opinion of PAVmed's value that differs from its market value or its book value, called intrinsic value, which is PAVmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PAVmed's market value can be influenced by many factors that don't directly affect PAVmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PAVmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if PAVmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PAVmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.